Full Breakdown
Merck Secures Global Rights to SciBrunch’s Experimental Cancer Drug in $400 Million Deal
By Drooid · · How we work
Deal Overview
On September 28, Merck announced that it will pay Chinese biotech firm SciBrunch Therapeutics a $400 million upfront fee for worldwide rights to an experimental cancer therapy. The agreement grants Merck the ability to develop, manufacture, and commercialize the drug outside of China, while SciBrunch retains the rights to market the product within the Chinese market.
Trend of U.S.–China Licensing Agreements
Merck’s transaction follows a growing pattern in which major U.S. pharmaceutical companies partner with Chinese biotech firms to access novel drug candidates. Chinese companies typically keep domestic commercialization rights and license their products abroad in exchange for upfront payments, milestone payments tied to development milestones, and royalty streams from future sales. Recent high-profile deals have highlighted this model as a pathway for U.S. firms to diversify pipelines and for Chinese innovators to monetize discoveries internationally.
Key Financial Terms
- Upfront payment: $400 million to SciBrunch Therapeutics.
- Milestone and royalty structure: While the exact amounts were not disclosed, the standard arrangement includes additional payments as the drug progresses through clinical phases and a percentage of sales revenue once the product reaches market.
These financial components reflect a broader industry practice of sharing development risk while providing immediate capital to Chinese developers.
Implications for Drug Development
The agreement expands Merck’s oncology portfolio and underscores the strategic importance of cross-border collaborations in accelerating access to emerging therapies. By securing global rights, Merck can integrate the experimental agent into its existing research and development framework, potentially shortening the timeline to market. For SciBrunch, the sizable upfront cash infusion supports continued research and domestic commercialization efforts, reinforcing China’s role as a source of innovative drug candidates.
Overall, the Merck-SciBrunch deal exemplifies how U.S. drugmakers are increasingly turning to Chinese biotech innovations to bolster their pipelines, a trend that may shape future pharmaceutical licensing strategies.